WO2019098634A1 - 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 - Google Patents
카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 Download PDFInfo
- Publication number
- WO2019098634A1 WO2019098634A1 PCT/KR2018/013769 KR2018013769W WO2019098634A1 WO 2019098634 A1 WO2019098634 A1 WO 2019098634A1 KR 2018013769 W KR2018013769 W KR 2018013769W WO 2019098634 A1 WO2019098634 A1 WO 2019098634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- schizophrenia
- formula
- disorder
- aripiprazole
- group
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- -1 carbamate compound Chemical class 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 14
- 230000000116 mitigating effect Effects 0.000 title abstract 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229960004372 aripiprazole Drugs 0.000 claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 239000012453 solvate Substances 0.000 claims abstract description 29
- 239000000126 substance Substances 0.000 claims abstract description 10
- 208000024891 symptom Diseases 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 208000006673 asthma Diseases 0.000 claims description 22
- 208000028017 Psychotic disease Diseases 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 6
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 5
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000024254 Delusional disease Diseases 0.000 claims description 4
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 3
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 208000017194 Affective disease Diseases 0.000 claims 2
- 206010033864 Paranoia Diseases 0.000 claims 2
- 208000027099 Paranoid disease Diseases 0.000 claims 2
- 208000036753 Schizophrenia, disorganised type Diseases 0.000 claims 2
- 208000024791 Schizotypal Personality disease Diseases 0.000 claims 2
- 230000003997 social interaction Effects 0.000 description 24
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 238000009472 formulation Methods 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 8
- 239000000164 antipsychotic agent Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003693 atypical antipsychotic agent Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229960001534 risperidone Drugs 0.000 description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 108091006082 receptor inhibitors Proteins 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005245 asenapine Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000009193 crawling Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003162 iloperidone Drugs 0.000 description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960001432 lurasidone Drugs 0.000 description 2
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960001057 paliperidone Drugs 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000001495 Disorganized Schizophrenia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940124604 anti-psychotic medication Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- GSHUZVSNIBLGMR-UHFFFAOYSA-N calcium;1,1-dioxo-1,2-benzothiazol-3-one Chemical compound [Ca].C1=CC=C2C(=O)NS(=O)(=O)C2=C1 GSHUZVSNIBLGMR-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
- 229960005123 cariprazine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940048820 edetates Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 101150091813 shfl gene Proteins 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- MWZFQMUXPSUDJQ-KVVVOXFISA-M sodium;[(z)-octadec-9-enyl] sulfate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCCOS([O-])(=O)=O MWZFQMUXPSUDJQ-KVVVOXFISA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a combination for preventing, alleviating or treating asthma, comprising a carbamate compound of the following formula (1), or a pharmaceutically acceptable salt, solvate or hydrate thereof, Mate compounds and aripiprazole.
- R 1 , R 2 , A 1 and A 2 are as defined herein.
- Schizophrenia is a representative psychiatric disorder, which is defined as the main pathology of thinking disorders, and is a collection of psychosomatic symptoms that manifest complex symptoms in various areas such as related, derived words, behavior, emotion, (syndrome), a series of symptoms that have long been known in human history as madness (madness).
- Symptoms of sudden onset can be classified as benign, negative, cognitive, and residual symptoms.
- Positive symptoms are abnormal and playful symptoms that appear on the surface, psychotic symptoms that can not be found in healthy people, abnormalities of sensation such as hallucination or hallucination, abnormalities of imagination such as unrealistic and playful delusions, There may be obstacles in the process.
- Negative symptoms are a dull state due to a decrease in normal emotional responses or behaviors. Predicted incidents, loss of motivation, social atrophy, etc., and generally the drug response is less favorable than positive symptoms.
- Cognitive symptoms are symptoms that are difficult to maintain concentration, and which impair their ability to learn new information or organize their thoughts.
- Schizophrenia includes depression, schizophrenia, schizophrenia, and unspecified schizophrenia, as well as compulsive schizophrenia, destructive schizophrenia, nervous schizophrenia and non-classified schizophrenia, as well as schizophrenia, schizophrenia, schizophrenia, Symptomatic disorders in a broad sense include affective disorders, delusional disorders, short term manifestations, shared psychotic disorders, psychotic disorders due to general medical disorders, psychotic disorders due to substance or psychotic disorders of unknown origin.
- Typical antipsychotic drugs such as haloperidol and chlorpromazine have been developed and atypical antipsychotic drugs such as aripiprazole, risperidone and clozapine have been developed. Especially, It is known to be effective. When drug therapy is started, psychomotor retardation and hallucination in acute phase are improved within a few days and reticence is also improved within several weeks. In most patients, when appropriate drugs are maintained in appropriate doses for 6-8 weeks, The part is known to improve. However, the first dose of antipsychotic medication may cause sleepiness or dizziness, and blurred vision, palpitations, menstrual changes, and skin rash may occur.
- the inventors of the present invention believed that the existing antipsychotic agent such as aripiprazole and the action mechanism thereof could be combined with other drugs to lower the dose required for the drug efficacy of existing antipsychotics and to maintain or increase the efficacy while alleviating side effects. Respectively.
- a carbamate compound of the following formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, has been selected as a drug having a mechanism of action different from that of a conventional antipsychotic agent:
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 8 alkyl, halo C 1 -C 8 alkyl, C 1 -C 8 thioalkoxy and C 1 -C 8 alkoxy,
- One of A 1 and A 2 is CH and the other is N.
- existing antipsychotic drugs include aripiprazole, asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, Atypical antipsychotics selected from the group consisting of quetiapine, risperidone and ziprasidone were selected.
- the atypical antipsychotic agent is aripiprazole.
- one embodiment of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising (a) a carbamate compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for the prevention, alleviation or treatment of asthma.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising, as an active ingredient, (a) a carbamate compound of the formula (1), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) a pharmaceutical composition comprising aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and further comprising at least one pharmaceutically acceptable carrier, for the prevention, alleviation or treatment of asthma .
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) a first composition comprising a carbamate compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) a second composition comprising aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in a container.
- the formulations and pharmaceutical compositions of the present invention provide for the prevention, alleviation or therapeutic effect of improved asthma without increasing side effects.
- the combinations and pharmaceutical compositions of the invention exhibit synergistic effects in the prevention, alleviation or treatment of asthma.
- the combinations and pharmaceutical compositions of the present invention are effective in treating negative symptoms of asthma and improving cognitive dysfunction.
- the combination and pharmaceutical composition of the present invention is a drug having a different mechanism of action from existing antipsychotics, and the combination of a carbamate compound of the formula (1) with a conventional atypical antipsychotic drug, aripiprazole, And the side effects of existing antipsychotic agents can be alleviated with maintaining or increasing the efficacy.
- Figure 1 shows the results of a social interaction animal behavior test related to the negative symptoms of the test compound and aripiprazole in an animal model in which amyotrophic similar symptoms were induced by treatment with dizocilpine (MK-801).
- the symbols in FIG. 1 are as follows:
- R 1 and R 2 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 8 alkyl, halo C 1 -C 8 alkyl, C 1 -C 8 thioalkoxy and C 1 -C 8 alkoxy,
- One of A 1 and A 2 is CH and the other is N.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising, as an active ingredient, (a) a carbamate compound of the formula (1), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) a pharmaceutical composition comprising aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and further comprising at least one pharmaceutically acceptable carrier, for the prevention, alleviation or treatment of asthma .
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising (a) a first composition comprising a carbamate compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) a second composition comprising aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in a container.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of (a) a carbamate compound of formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof; And (b) aripiprazole, or a pharmaceutically acceptable salt, solvate or hydrate thereof, to a subject for treatment, prevention or alleviation.
- components (a) and (b) in the combination may be administered simultaneously, separately or sequentially.
- the first composition and (b) the second composition (b) may be administered simultaneously, separately or sequentially.
- the components (a) and (b) in the preventive, palliative or therapeutic method can be administered to the subject simultaneously, separately or sequentially.
- the components (a) and (b) may be administered simultaneously, separately or sequentially.
- R 1 and R 2 in the general formula (1) are each independently selected from the group consisting of hydrogen, halogen and C 1 -C 8 alkyl.
- a halo-C 1 -C 8 alkyl is a perfluoroalkyl.
- the carbamate compound of Formula 1 is carbamic acid (R) -1- (2-chlorophenyl) -2-tetrazol-2-yl) ethyl ester of Formula 2:
- the carbamate compounds of Formulas (1) and (2) above can be prepared by using known compounds or compounds which can be easily prepared therefrom, as long as those skilled in the art are familiar with the synthesis of the compounds.
- the process for preparing the compound of formula 1 is described in detail in WO 2006/112685 A1, WO 2010/150946 A1 and WO 2011/046380 A2, which are incorporated herein by reference.
- the compound of the formula (1) can be synthesized chemically by the method described in the above document, but it is merely a suggestion of one exemplary method, and the order of the unit operation and the like can be selectively changed as necessary, Is not intended to limit.
- Aripiprazole is a product marketed under the trade name Abilify®.
- the compound was named 7- ⁇ 4- [4- (2,3-dichlorophenyl) piperazin-1-yl] butoxy ⁇ -3,4-dihydroquinolin-2 (1H) 4-dihydroquinolin-2 (1H) -one), the structure of which is as follows:
- aripiprazole in addition to aripiprazole, asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, quetiapine ( quetiapine, risperidone, and ziprasidone, can also be preferably used.
- the free form of each of the compounds of formula 1 or 2 and the aripiprazole is used.
- the compound of formula 1 or 2 or a pharmaceutically acceptable salt of aripiprazole can be, for example, independently selected from the group consisting of acetate, benzenesulfonate, benzoate, bitartrate, calcium acetate, camsylate, But are not limited to, nitrates, nitrates, citrates, edetates, eddylates, esters, esters, fumarates, glutamates, gluconates, glutamates, glycolylarsanylate, hexylresorcinate, hydrabamine, hydrobromide,
- the present invention also relates to a pharmaceutical composition comprising at least one compound selected from the group consisting of hydrochloride, hydrogencarbonate, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maliateate, mandelate, mesylate, methylnitrate, Ketates, lead silicates,
- Salicylates stearates, subacetates, succinates or hemi-succinates, sulphates or hemi-sulphates, tannates, tartrates, oxalates or hemi-tartrates, theoclates, triethiodides , Benzenetine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, ammonium, tetramethylammonium, calcium, lithium, magnesium, potassium, sodium and zinc.
- the therapeutically effective amount or dose of the compound of formula (I) is 12.5 to 500 mg, 12.5 to 400 mg , 25 to 400 mg, 25 to 300 mg, 25 to 200 mg, 50 to 400 mg, 50 to 300 mg, 50 to 200 mg, or 100 to 200 mg.
- the therapeutically effective amount or dose of aripiprazole is in the range of 5 to 90 mg, preferably 5 to 60 mg , And more preferably 5 to 30 mg.
- the dose of an atypical antipsychotic agent may be less than that required to indicate a therapeutically effective amount when administered alone without the carbamate compound of formula (I). This is because the combination with the carbamate compound of the formula (1) can maintain the effective drug efficacy while lowering the dose required for the drug efficacy of the atypical antipsychotic agent.
- a pharmaceutical composition comprising: a) a carbamate compound of formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof; Or a pharmaceutically acceptable salt, solvate or hydrate thereof is in the range of from 1: 1 to 40: 1, from 1: 1 to 20: 1, from 2: 1 to 20: 1, or from 2: 1 To 10: 1.
- compositions and pharmaceutical compositions of the present invention may be formulated into various forms of oral or parenteral formulations, for example, by intravenous injection, intramuscular injection, intracutaneous, subcutaneous injection, intraduodenal, May be administered by injection or intraperitoneal, by intrathecal injection, or by transdermal route.
- the composition may be administered by any device capable of transferring the active agent to the target cell.
- the route to be administered may vary depending upon the general condition and age of the subject to be treated, the nature of the treatment condition and the active ingredient selected.
- Suitable dosages of the combination or pharmaceutical composition according to one embodiment of the present invention may vary depending on factors such as the formulation method, the mode of administration, the age, weight, sex, pathological condition, food, administration time, route of administration, Factors, and the ordinarily skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis.
- the pharmaceutical composition according to one embodiment may be administered in one or more doses, for example, one to four times per day.
- the pharmaceutical composition comprises, on a free-form basis, a) 12.5 to 500 mg, 12.5 to 400 mg, 25 to 400 mg, 25 to 300 mg, 25 to 200 mg, 50 to 400 mg, mg, 50 to 300 mg, 50 to 200 mg, or 100 to 200 mg; b) 5 to 90 mg, preferably 5 to 60 mg, more preferably 5 to 30 mg of aripiprazole.
- the pharmaceutical composition according to one embodiment of the present invention may be formulated using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs May be prepared in unit dosage form or may be manufactured by intrusion into a multi-dose container.
- the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
- the pharmaceutical composition may be administered in the form of suppositories, sprays, ointments, creams, gels, inhalants or skin patches.
- the pharmaceutical composition may also be prepared for mammalian administration, more preferably for human administration.
- the pharmaceutical composition of the present invention includes, in addition to the above-described active ingredients (a) and (b), at least one pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may be solid or liquid and may be in the form of pharmaceutical preparations such as excipients, antioxidants, buffers, bacteriostats, dispersants, adsorbents, surfactants, binders, preservatives, disintegrants, sweeteners, flavors, lubricants, release modifiers, Stabilizers, suspending agents, and lubricants.
- pharmaceutically acceptable carriers may be selected from saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and mixtures thereof.
- suitable fillers include sugars (such as dextrose, sucrose, maltose and lactose), starches (such as corn starch), sugar alcohols (e.g., mannitol, sorbitol, maltitol, erythritol, Starch hydrolyzates (e.g., dextrin and maltodextrin), celluloses or cellulose derivatives (such as microcrystalline cellulose), or mixtures thereof, but are not limited thereto.
- sugars such as dextrose, sucrose, maltose and lactose
- starches such as corn starch
- sugar alcohols e.g., mannitol, sorbitol, maltitol, erythritol, Starch hydrolyzates (e.g., dextrin and maltodextrin), celluloses or cellulose derivatives (such as microcrystalline cellulose), or mixtures thereof, but are not limited thereto.
- sugar alcohols e.g.
- suitable antioxidants include, but are not limited to tocopherol, ascorbic acid, gallate, and the like.
- a suitable buffer may be citric acid monohydrate
- suitable emulsifiers include anionic, cationic or nonionic surfactants such as sodium laurate, sodium lauryl sulfate, sodium dodecanesulfonate, sodium oleyl sulfate, benzalkonium chloride, But are not limited to, alkyltrimethylammonium bromide, glyceryl monooleate, polyoxyethylene-dried sorbitan fatty acid esters, polyvinyl alcohol and dried sorbitan esters or mixtures thereof.
- anionic, cationic or nonionic surfactants such as sodium laurate, sodium lauryl sulfate, sodium dodecanesulfonate, sodium oleyl sulfate, benzalkonium chloride, But are not limited to, alkyltrimethylammonium bromide, glyceryl monooleate, polyoxyethylene-dried sorbitan fatty acid esters, polyvinyl alcohol and dried sorbitan esters or mixtures thereof.
- suitable binders include povidone, copovidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, gum, sucrose, starch or Mixtures of these may be used, but are not limited thereto.
- suitable preservatives include, but are not limited to, benzoic acid, sodium benzoate, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, gallate, hydroxybenzoate, EDTA, But is not limited thereto.
- suitable disintegrants include starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starch, microcrystalline cellulose, or mixtures thereof But is not limited thereto.
- suitable sweeteners may be sucralose, saccharin, sodium or potassium or calcium saccharin, acesulfame potassium or sodium cyclamate, mannitol, fructose, sucrose, maltose or mixtures thereof It is not limited.
- a suitable glidant may be, but is not limited to, colloidal silicon dioxide.
- suitable release-modifying excipients include, but are not limited to, pH-independent polymers such as hydroxypropylmethylcellulose, polyethylene oxide, carbomer, alginic acid, and the like, But is not limited thereto.
- suitable wetting agents include, but are not limited to, hypromellose (HPMC), polyoxyethylene derivatives of sorbitan esters such as polysorbate 20 and polysorbate 80, lecithin, polyoxyethylene- and polyoxypropylene ethers, Sodium deoxycholate, or mixtures thereof, but are not limited thereto.
- HPMC hypromellose
- polyoxyethylene derivatives of sorbitan esters such as polysorbate 20 and polysorbate 80
- lecithin polyoxyethylene- and polyoxypropylene ethers
- Sodium deoxycholate or mixtures thereof, but are not limited thereto.
- suitable suspending agents include cellulose derivatives such as microcrystalline cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, alginate, chitosan, dex Tran, gelatin, polyethylene glycol, polyoxyethylene- and polyoxypropylene ether, or mixtures thereof, but are not limited thereto.
- suitable lubricants include, but are not limited to, long chain fatty acids and salts thereof, such as magnesium stearate and stearic acid, talc, glyceride wax, or mixtures thereof.
- the pharmaceutical composition of the present invention may be formulated into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- the carrier is a finely divided solid which is mixed with the active ingredient in the form of a mixture.
- the active ingredient may be mixed with the carrier to have binding characteristics that can be titrated in the appropriate proportions and size and size desired.
- the pharmaceutical composition of the present invention can be prepared in the form of a capsule.
- the pharmaceutical composition of the present invention can be administered on a free-form basis to a patient in need of a) 12.5 to 500 mg, 12.5 to 400 mg, 25 to 400 mg, 25 to 300 mg, 25 to 200 mg, 50 to 400 mg, 50 To 300 mg, 50 to 200 mg, or 100 to 200 mg; b) 5 to 90 mg, preferably 5 to 60 mg, more preferably 5 to 30 mg of aripiprazole; And capsules comprising gelatin and titanium dioxide as a capsule base. The amount can be adjusted as needed.
- compositions and pharmaceutical compositions of the present invention have medicinal uses for the prevention, amelioration or treatment of asthma.
- the symptom of the asthmatic disease may be at least one selected from the group consisting of positive symptoms, negative symptoms, cognitive symptoms and residual symptoms of asthma.
- the outbreak disease is selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, Schizophrenia, schizophreniform disorder, schizophreniform disorder, delusional disorder, short-term schizophrenia, shared psychosis disorder, generalized schizophrenia, schizophrenia, schizophrenia, schizophrenia, schizophrenia, schizophrenia, schizophrenia A psychotic disorder caused by a medical condition, a psychotic disorder caused by a substance, and an unexplained psychotic disorder.
- the animal behavior test can be used to test the antipsychotic activity of carbamate compounds and aripiprazole of formula 1 against asthma (Neill JC , Grayson B, Kiss B, Gyertyan I, Ferguson P, Adham N, Effects of cariprazine, a novel antipsychotic, oncognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology., Eur Neuropsychopharmacol. 3-14).
- (NMDA) receptor antagonist was administered to animals and the effect of N-methyl-D-aspartate (NMDA) .
- MK-801-induced social interaction induced by dinosilpine MK-801
- NMDA N-methyl-D-aspartate receptor inhibitor
- Aripiprazole known as an atypical antipsychotic, inhibits amyotrophic-like symptoms in proportion to the dose of diisonamine (Deiana S, Watanabe A, Yamasaki Y, Amada N, Kikuchi T, Stott C, Riedel G, -induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behav Pharmacol. 2015 Dec; 26 (8 Spec No): 748-65).
- the dosage of the carbamate compound of formula (I) and aripiprazole for preventing, alleviating or treating the disease will usually vary depending on the severity of the disease, the weight and metabolic status of the subject being treated.
- a "therapeutally effective amount " for an individual patient means an amount sufficient to achieve the pharmacological effect, i.
- preventing As used herein, the terms “ preventing ", “ preventing “, and “ prevention” are intended to reduce the likelihood of or susceptibility to disease.
- alleviate refers to alleviating all or part of the disease and /
- treat refers to the elimination of all or part of the disease and / or its attendant symptoms.
- subject refers to an animal, preferably a mammal (e.g., primates (e.g., a person), cow, sheep, goat, horse, dog , A cat, a rabbit, a mouse, a mouse, etc.), and most preferably a human.
- a mammal e.g., primates (e.g., a person), cow, sheep, goat, horse, dog , A cat, a rabbit, a mouse, a mouse, etc.
- therapeutically effective amount is intended to be sought by a researcher, veterinarian, physician or other clinician, and refers to any biological or medicinal agent in the system, animal or human, including alleviating the symptoms of the disease or disorder Quot; means the amount of active compound or pharmaceutical agent that elicits the response.
- combination or combination or “ combined therapy” refers to the use of two or more drugs together and does not necessarily mean that two or more drugs are necessarily mixed .
- Two or more drugs may be present together in a single preparation in a mixed state or may be used as separate preparations. That is, “ formulations " encompass both a single formulation and two separate preparations, allowing simultaneous, separate or sequential administration.
- composition refers to a single formulation in which two or more drugs are present in admixture.
- kit refers to a finished article, and refers to an article containing two or more drugs in the form of a combination. Two or more drugs may be packaged in a single formulation and administered simultaneously in the article, or packaged in two separate preparations in the article, and administered simultaneously, separately, or sequentially.
- test compound 2-tetrazol-2-yl) ethyl ester
- mice Male rats (Wistar, 4 weeks old, Orient Bio Co., Ltd.) were purchased and divided into two groups in an animal breeding room, and they were adapted for one week or more on separate shelves. Experimental animals were maintained in an environment with a 12-hour light / dark cycle at a temperature of 22-25 ° C and a relative humidity of 40-60%, and in an environment free of water and food. They were kept and maintained in accordance with laboratory animal control standards. The rats were stabilized for more than a week and then used in a social interaction animal behavior test in pairs in which the weight difference was not exceeded by 20 g.
- NMDA N-methyl-D-aspartate
- Dicosylpin (purchased from Sigma) was dissolved in physiological saline used as a vehicle to be newly prepared. A dose of 0.1 mg / kg was administered subcutaneously in a volume of 1 ml per 1 kg of rat body weight 4 hours before the experiment.
- Aripiprazole and the test compound were newly prepared by dissolving in 30% polyethylene glycol 400 (Sigma) used as a vehicle.
- aripiprazole was administered at a dose of 1 ml per kg body weight, aripiprazole at a dose of 0.003 mg / kg , The test compound was orally administered at a dose of 3 mg / kg.
- the total time average of active social interactions in the group of negative control treated with dicosylphine was 53.86 ⁇ 2.90 sec.
- the total time average of positive social interactions in the positive control group of the vehicle was 69.63 ⁇ 3.13 sec, and aripiprazole 0.003 57.52 ⁇ 3.04 sec in the mg / kg group, 56.78 ⁇ 2.19 sec in the 3 mg / kg group, and 63.76 ⁇ 1.87 sec in the group administered with the aripiprazole 0.003 mg / kg and the test compound 3 mg / kg.
- the total time of positive social interaction of the test compound and / or aripiprazole treated vehicle group and the vehicle group as a positive control is shown in Table 2 as the recovery rate (%) compared to the negative control treated with only the dinosylphenol.
- the recovery rate was calculated as follows.
- Aripiprazole-treated group and test compound-treated group showed recovery rates of 23.2% and 18.5%, respectively, compared with the negative control group, and there was no statistically significant difference from the negative control group treated with only the dinocylpinone group and statistically significant difference from the positive control group.
- Aripiprazole 0.003 mg / kg which did not show a significant recovery effect compared to the negative control group, showed a recovery rate of 62.8% compared with the negative control group in the case of administration of the test compound 3 mg / kg, showing a statistically significant difference from the negative control group , And there was no statistically significant difference from the positive control group (Fig. 1).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (22)
- 제1항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 화학식 1의 화합물을 유리형 기준으로 12.5 mg 내지 500 mg의 양으로 포함하는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 아리피프라졸을 유리형 기준으로 5 mg 내지 90 mg의 양으로 포함하는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 화학식 1의 화합물을 유리형 기준으로 12.5 mg 내지 500 mg 포함하고, 아리피프라졸을 유리형 기준으로 5 mg 내지 90 mg 포함하는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 조현병이 양성 증상, 음성 증상, 인지 증상 및 잔류 증상으로 이루어진 군으로부터 선택되는 하나 이상의 증상을 나타내는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 조현병이 편집증 유형 정신분열증, 해체 유형 정신분열증, 균열 유형 정신분열증, 구분화되지 않은 정신분열증, 잠복형 정신분열증, 정신분열병 후 우울증, 전류 정신분열병, 단순 정신분열병, 불특정 정신분열병, 정신분열형장애, 정신분열정동장애, 망상장애, 단기 조현병, 공유 정신증 장애, 일반적 의학 질환으로 인한 정신증 장애, 물질로 인한 정신증 장애 및 원인 불명의 정신증 장애로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는 배합물.
- 제1항에 있어서, 포유 동물 투여용인 것을 특징으로 하는 배합물.
- 제1항에 있어서, 성분 (a) 및 (b)가 동시에 또는 순차적으로 투여되는 것을 특징으로 하는 배합물.
- 제1항에 있어서, 성분 (a) 및 (b)가 별개로 투여되는 것을 특징으로 하는 배합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 키트 형태인 것을 특징으로 하는 배합물.
- 제12항에 있어서, (a) 화학식 1의 카바메이트 화합물, 또는 그의 약제학적으로 허용가능한 염, 용매화물 또는 수화물을 포함하는 제1 조성물; 및 (b) 아리피프라졸, 또는 그의 약제학적으로 허용가능한 염, 용매화물 또는 수화물을 포함하는 제2 조성물을 용기 내에 함유하는 것을 특징으로 하는 배합물.
- (a) 하기 화학식 1의 카바메이트 화합물, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물; 및 (b) 아리피프라졸, 또는 이의 약제학적으로 허용가능한 염, 용매화물 또는 수화물을 포함하고, 추가로 약제학적으로 허용되는 담체를 1종 이상 포함하는, 조현병의 예방, 경감 또는 치료용 약제학적 조성물:[화학식 1]상기 화학식 1에서,R1 및 R2는 각각 독립적으로 수소, 할로겐, C1-C8 알킬, 할로 C1-C8 알킬, C1-C8 티오알콕시 및 C1-C8 알콕시로 이루어진 그룹으로부터 선택되고,A1 및 A2에서 어느 하나는 CH이며, 다른 하나는 N이다.
- 제14항에 있어서, R1 및 R2가 각각 독립적으로 수소, 할로겐 및 C1-C8 알킬로 이루어진 그룹으로부터 선택되는 것을 특징으로 하는 약제학적 조성물.
- 제14항에 있어서, 조현병이 양성 증상, 음성 증상, 인지 증상 및 잔류 증상으로 이루어진 군으로부터 선택되는 하나 이상의 증상을 나타내는 것을 특징으로 하는 약제학적 조성물.
- 제14항에 있어서, 조현병이 편집증 유형 정신분열증, 해체 유형 정신분열증, 균열 유형 정신분열증, 구분화되지 않은 정신분열증, 잠복형 정신분열증, 정신분열병 후 우울증, 전류 정신분열병, 단순 정신분열병, 불특정 정신분열병, 정신분열형장애, 정신분열정동장애, 망상장애, 단기 조현병, 공유 정신증 장애, 일반적 의학 질환으로 인한 정신증 장애, 물질로 인한 정신증 장애 및 원인 불명의 정신증 장애로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는 약제학적 조성물.
- 제14항 내지 제18항 중 어느 한 항에 있어서, 포유 동물 투여용으로 제조된 것임을 특징으로 하는 약제학적 조성물.
- 제14항 내지 제18항 중 어느 한 항에 있어서, 화학식 1의 화합물을 유리형 기준으로 12.5 mg 내지 500 mg의 양으로 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제14항 내지 제18항 중 어느 한 항에 있어서, 아리피프라졸을 유리형 기준으로 5 mg 내지 90 mg의 양으로 포함하는 것을 특징으로 하는 약제학적 조성물.
- 제14항 내지 제18항 중 어느 한 항에 있어서, 화학식 1의 화합물을 유리형 기준으로 12.5 mg 내지 500 mg 포함하고, 아리피프라졸을 유리형 기준으로 5 mg 내지 90 mg 포함하는 것을 특징으로 하는 약제학적 조성물.
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18878582.8A EP3711759A4 (en) | 2017-11-14 | 2018-11-13 | MIXTURE CONTAINING A CARBAMATE COMPOUND FOR THE PREVENTION, MITIGATION OR TREATMENT OF SCHIZOPHRENIA |
US16/763,604 US11116751B2 (en) | 2017-11-14 | 2018-11-13 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
CN201880073904.3A CN111432813B (zh) | 2017-11-14 | 2018-11-13 | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 |
BR112020009310-6A BR112020009310A2 (pt) | 2017-11-14 | 2018-11-13 | combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia. |
IL274437A IL274437B1 (en) | 2017-11-14 | 2018-11-13 | A mixture containing a carbamate compound for the prevention, relief or treatment of schizophrenia |
MX2020004975A MX2020004975A (es) | 2017-11-14 | 2018-11-13 | Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. |
RU2020119301A RU2772465C2 (ru) | 2017-11-14 | 2018-11-13 | Смесь, содержащая карбаматное соединение для предотвращения, облегчения или лечения шизофрении |
CN202311249452.9A CN117064892A (zh) | 2017-11-14 | 2018-11-13 | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 |
CA3081226A CA3081226A1 (en) | 2017-11-14 | 2018-11-13 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
KR1020207013847A KR20200074157A (ko) | 2017-11-14 | 2018-11-13 | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 |
AU2018367733A AU2018367733A1 (en) | 2017-11-14 | 2018-11-13 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
JP2020544729A JP7355747B2 (ja) | 2017-11-14 | 2018-11-13 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
US17/397,177 US11717509B2 (en) | 2017-11-14 | 2021-08-09 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
US18/210,215 US20230321041A1 (en) | 2017-11-14 | 2023-06-15 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
JP2023122283A JP2023139233A (ja) | 2017-11-14 | 2023-07-27 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0151253 | 2017-11-14 | ||
KR20170151253 | 2017-11-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/763,604 A-371-Of-International US11116751B2 (en) | 2017-11-14 | 2018-11-13 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
US17/397,177 Continuation US11717509B2 (en) | 2017-11-14 | 2021-08-09 | Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019098634A1 true WO2019098634A1 (ko) | 2019-05-23 |
Family
ID=66539804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/013769 WO2019098634A1 (ko) | 2017-11-14 | 2018-11-13 | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 |
Country Status (11)
Country | Link |
---|---|
US (3) | US11116751B2 (ko) |
EP (1) | EP3711759A4 (ko) |
JP (2) | JP7355747B2 (ko) |
KR (1) | KR20200074157A (ko) |
CN (2) | CN117064892A (ko) |
AU (1) | AU2018367733A1 (ko) |
BR (1) | BR112020009310A2 (ko) |
CA (1) | CA3081226A1 (ko) |
IL (1) | IL274437B1 (ko) |
MX (1) | MX2020004975A (ko) |
WO (1) | WO2019098634A1 (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
WO2006112685A1 (en) | 2005-04-22 | 2006-10-26 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
WO2010150946A1 (en) | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
WO2011046380A2 (en) | 2009-10-15 | 2011-04-21 | Sk Holdings Co.,Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
US20120004211A1 (en) * | 2006-11-10 | 2012-01-05 | Laboratorios Del Dr. Esteve, S.A. | 1,2,4-triazole derivatives as sigma receptor inhibitors |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US20170029382A1 (en) * | 2015-07-31 | 2017-02-02 | The Johns Hopkins University | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels |
WO2017066590A1 (en) * | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200848041A (en) * | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
RU2610169C2 (ru) * | 2014-09-11 | 2017-02-08 | Общество С Ограниченной Ответственностью "Валентек" | ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ |
US20170246148A1 (en) * | 2014-09-15 | 2017-08-31 | Sound Pharmaceuticals Incorporated | Methods and Compositions for Treating Psychotic Disorders |
WO2016065586A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Pyrazole, triazole and tetrazole orexin receptor antagonists |
US11221329B2 (en) * | 2015-10-30 | 2022-01-11 | Lieber Institute, Inc. | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
KR20180068493A (ko) * | 2016-12-14 | 2018-06-22 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
CN114867469A (zh) * | 2019-11-22 | 2022-08-05 | 爱思开生物制药株式会社 | 包含氨基甲酸酯化合物的口服药物组合物及其制备方法 |
-
2018
- 2018-11-13 CN CN202311249452.9A patent/CN117064892A/zh active Pending
- 2018-11-13 BR BR112020009310-6A patent/BR112020009310A2/pt unknown
- 2018-11-13 CN CN201880073904.3A patent/CN111432813B/zh active Active
- 2018-11-13 KR KR1020207013847A patent/KR20200074157A/ko active Search and Examination
- 2018-11-13 AU AU2018367733A patent/AU2018367733A1/en active Pending
- 2018-11-13 EP EP18878582.8A patent/EP3711759A4/en active Pending
- 2018-11-13 US US16/763,604 patent/US11116751B2/en active Active
- 2018-11-13 IL IL274437A patent/IL274437B1/en unknown
- 2018-11-13 WO PCT/KR2018/013769 patent/WO2019098634A1/ko unknown
- 2018-11-13 CA CA3081226A patent/CA3081226A1/en active Pending
- 2018-11-13 JP JP2020544729A patent/JP7355747B2/ja active Active
- 2018-11-13 MX MX2020004975A patent/MX2020004975A/es unknown
-
2021
- 2021-08-09 US US17/397,177 patent/US11717509B2/en active Active
-
2023
- 2023-06-15 US US18/210,215 patent/US20230321041A1/en active Pending
- 2023-07-27 JP JP2023122283A patent/JP2023139233A/ja active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
WO2006112685A1 (en) | 2005-04-22 | 2006-10-26 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
KR101286499B1 (ko) * | 2005-04-22 | 2013-07-16 | 에스케이바이오팜 주식회사 | 신경치료용 아졸 화합물 |
US20120004211A1 (en) * | 2006-11-10 | 2012-01-05 | Laboratorios Del Dr. Esteve, S.A. | 1,2,4-triazole derivatives as sigma receptor inhibitors |
WO2010150946A1 (en) | 2009-06-22 | 2010-12-29 | Sk Holdings Co., Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
WO2011046380A2 (en) | 2009-10-15 | 2011-04-21 | Sk Holdings Co.,Ltd. | Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester |
WO2013131018A1 (en) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
US20170029382A1 (en) * | 2015-07-31 | 2017-02-02 | The Johns Hopkins University | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels |
WO2017066590A1 (en) * | 2015-10-16 | 2017-04-20 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
Non-Patent Citations (5)
Title |
---|
BIALER, M. ET AL.: "Progress Report on New Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII)", EPILEPSY RESEARCH, vol. 111, March 2015 (2015-03-01), pages 85 - 141, XP055611172 * |
DEIANA SWATANABE AYAMASAKI YAMADA NKIKUCHI TSTOTT CRIEDEL G: "MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol", BEHAV PHARMACOL., vol. 26, no. 8, December 2015 (2015-12-01), pages 748 - 65 |
IMBRICI, P. ET AL.: "Major Channels Involved in Neuropsychiatric Disorders and Therapeutic Perspectives", FRONTIERS IN GENETICS, vol. 4, no. 76, 7 May 2013 (2013-05-07), pages 1 - 19, XP055611174 * |
NEILL JCGRAYSON BKISS BGYERTYAN IFERGUSON PADHAM N: "Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.", EUR NEUROPSYCHOPHARMACOL., vol. 26, no. l, January 2016 (2016-01-01), pages 3 - 14 |
RUNG JPCARLSSON ARYDEN MARKINHUHTA KCARLSSON ML: "+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia", PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, vol. 29, no. 5, June 2005 (2005-06-01), pages 827 - 32, XP025311018, DOI: 10.1016/j.pnpbp.2005.03.004 |
Also Published As
Publication number | Publication date |
---|---|
CN117064892A (zh) | 2023-11-17 |
RU2020119301A (ru) | 2021-12-15 |
EP3711759A4 (en) | 2021-11-24 |
JP7355747B2 (ja) | 2023-10-03 |
RU2020119301A3 (ko) | 2021-12-15 |
US20230321041A1 (en) | 2023-10-12 |
JP2023139233A (ja) | 2023-10-03 |
US11717509B2 (en) | 2023-08-08 |
IL274437B1 (en) | 2024-05-01 |
CA3081226A1 (en) | 2019-05-23 |
KR20200074157A (ko) | 2020-06-24 |
MX2020004975A (es) | 2020-08-24 |
AU2018367733A1 (en) | 2020-05-21 |
BR112020009310A2 (pt) | 2020-10-13 |
CN111432813B (zh) | 2024-01-09 |
EP3711759A1 (en) | 2020-09-23 |
CN111432813A (zh) | 2020-07-17 |
US20200281895A1 (en) | 2020-09-10 |
JP2021503012A (ja) | 2021-02-04 |
US11116751B2 (en) | 2021-09-14 |
IL274437A (en) | 2020-06-30 |
US20210361622A1 (en) | 2021-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060204486A1 (en) | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases | |
CA2626134C (en) | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders | |
JP7082162B2 (ja) | マイボーム機能不全の治療剤 | |
WO2014163400A1 (ko) | 도네페질을 포함하는 비경구투여용 약제학적 조성물 | |
CA2985366A1 (en) | Methods of treating a neurodegenerative disease | |
WO2014171748A1 (ko) | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 | |
MXPA00012957A (es) | Composicion para dosis oral de liberacion extendida. | |
CA2167004C (en) | Agent for treating mental disorders associated with cerebrovascular disorders | |
WO2019108021A2 (ko) | 토파시티닙을 포함하는 약제학적 조성물 | |
WO2016013795A1 (ko) | 서방성 제제 | |
WO2018111008A1 (ko) | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2012148181A2 (ko) | 약물 방출제어용 조성물 | |
WO2019098634A1 (ko) | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 | |
WO2012077968A2 (en) | Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof | |
WO2014157852A1 (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
WO2018111009A1 (ko) | 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2022075760A1 (ko) | 아프레밀라스트를 함유하는 약학 조성물 | |
WO2019098630A1 (ko) | 취약 x 증후군, 엔젤만 증후군 또는 렛 증후군을 포함하는 발달 장애의 경감 또는 치료를 위한 카바메이트 화합물의 용도 | |
WO2016137266A2 (ko) | 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물 | |
WO2013002578A2 (ko) | 조루증 치료용 약학 조성물 및 조루증 치료 방법 | |
WO2014157851A1 (ko) | 저장 및 pH 안정성이 개선된 에페리손 의약 조성물 | |
AU2020452385A1 (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
WO2020017808A1 (ko) | 날푸라핀 함유 구강붕해정 | |
JP2023510082A (ja) | 認知症患者における行動・心理症状を治療するための方法 | |
WO2022015087A1 (ko) | 이중 억제제 화합물 및 이들의 의약 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18878582 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3081226 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020544729 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20207013847 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018367733 Country of ref document: AU Date of ref document: 20181113 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018878582 Country of ref document: EP Effective date: 20200615 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020009310 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020009310 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200511 |